

# Enuresis

## Enuresis

Enuresis, or bedwetting, describes urinary incontinence during sleep in any child over the age of 5 years, in the absence of - congenital or acquired neurological disorders. Monosymp - tomatic enuresis (MSE) is defined as enuresis without any other urinary symptoms; primary MSE describes those who have never achieved night-time continence, whereas secondary MSE refers to those who develop enuresis after a dry period of at least 6 months. Enuresis with any daytime LUTS is defined as non-monosymptomatic enuresis (NMSE). By 15 years of age 1-2% will suffer from enuresis and the prevalence in adults is 0.5%.

Investigation Three underlying pathophysiological mechanisms are predominantly implicated in enuresis and should be evaluated clinically . 1 Nocturnal detrusor overactivity and reduced nocturnal bladder capacity . Up to half of all children overactivity or reduced functional capacity , in the absence of nocturnal polyuria. Patients should be investigated initially with a bladder diary to assess daytime and night-time frequency and incontinence episodes, as well as to assess functional capacity . Urodynamics should be reserved for those who fail initial therapy; if detrusor overactivity is present then patients should be managed with antimuscarinics or  $\beta$ -agonists. 2 Nocturnal polyuria . Increased nocturnal urine production (defined as a nocturnal urine output exceeding 130% of expected bladder capacity for age), which may be due to increased intake or underlying medical conditions, should be identified on a bladder diary and investigated further if present (e.g. diabetes insipidus, obstructive sleep apnoea). 3 Arousal and sleep disorders . Children with enuresis are typically unable to wake from sleep to void, and it is thought that arousal disorders may account for part of the pathogenesis of this condition. Evaluation by a sleep specialist should be considered as part of the management strategy for children in whom sleep disorders are suspected. Treatment The treatment of enuresis consists initially of behavioural management techniques. These include fluid modification (night-time fluid restriction, reducing sugary , caffeinated and fizzy drink intake), bedwetting alarms, star charts and rewards systems, and maintaining regular bowel habits. If this fails to improve symptoms and the child is experiencing distress from these symptoms, pharmacological therapy should be considered. Desmopressin, a synthetic analogue of antidiuretic hormone, is best suited for those with nocturnal polyuria with normal bladder function, whereas antimuscarinics and  $\beta$ -agonists should be considered for those with low functional capacity or those who have failed to respond to desmopressin.

tract dysfunction. Storage-phase  
Treatment options disorder CISC  
Low compliance/ detrusor  
Overnight catheter drainage  
overactivity/low Pharmacological  
therapy a capacity Antimuscarinic  
-agonist 3 Minimally invasive  
therapy Intravesical BTX-A Surgical  
therapy Augmentation cystoplasty  
Urinary diversion Low outlet  
Bladder neck bulking agent  
injection resistance Bladder neck  
sling or bladder neck  
reconstruction Arti /f\_ i cial urinary  
sphincter Voiding-phase disorder  
Detrusor-sphincter CISC a

dyssynergia Overnight catheter  
drainage Pharmacological therapy  
Antimuscarinic -agonist 3  
Minimally invasive therapy  
Intravesical and intrasphincteric  
BTX-A Neuromodulation Surgical  
therapy Augmentation cystoplasty  
Urinary diversion Detrusor CISC  
underactivity Overnight catheter  
drainage Neuromodulation BTX-A,  
botulinum toxin A; CISC, clean  
intermittent self

catheterisation. a Risk of renal function deterioration. (a) (b) Figure 83.10 Urachal anomalies. (a)  
Normal; (b) patent urachus;

---

Revision #1

Created 2025-12-31 15:30:08 UTC by Omar Ayman

Updated 2025-12-31 15:30:08 UTC by Omar Ayman